MEDP Earnings Date: Feb 8, 2027 (Estimated) — Medpace Holdings, Inc.
NASDAQ · Healthcare · Diagnostics & Research
Updated
When is MEDP's next earnings date?
Medpace Holdings, Inc. (MEDP) is expected to report Q4 2026 earnings on Monday, February 8, 2027 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $4.68 on revenue of $719.1M.
How did MEDP do in its last earnings report?
In its most recent report on Oct 21, 2026 (Q3 2026), Medpace Holdings, Inc. posted EPS of $4.84 versus the $4.42 estimate, a beat of 9.5%. Revenue was $716.0M against a $714.4M estimate. The stock's 1-day post-earnings move was -1.3%.
How much does MEDP stock move after earnings?
MEDP beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 16.0% (up or down) in the day after earnings.
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
🤖 AI Earnings Analysis
Medpace's clinical-research business delivered a quality EPS beat: Q3 revenue rose 8.5% YoY to $716M while EPS climbed 25% to $4.84; FY revenue guidance is $2.8–$2.9B.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-21 | Q3 2026 | 4.42 | 4.84 | +9.50% | $716.0M | ✅ Beat | -1.29% | +4.56% | — |
| 2026-07-22 | Q2 2026 | 3.99 | 4.25 | +6.52% | $707.3M | ✅ Beat | +14.71% | +10.76% | +16.00% |
| 2026-04-22 | Q1 2026 | 3.87 | 4.28 | +10.59% | $706.6M | ✅ Beat | -22.63% | -18.66% | -15.41% |
| 2026-02-09 | Q4 2025 | 4.21 | 4.67 | +10.93% | $708.5M | ✅ Beat | -15.90% | -19.26% | -9.92% |
| 2025-10-22 | Q3 2025 | 3.54 | 3.86 | +9.04% | $659.9M | ✅ Beat | +9.12% | +6.92% | +7.21% |
| 2025-07-21 | Q2 2025 | 2.99 | 3.10 | +3.68% | $603.3M | ✅ Beat | +54.67% | +46.68% | +49.62% |
| 2025-04-21 | Q1 2025 | 3.08 | 3.67 | +19.16% | $558.6M | ✅ Beat | -2.32% | +3.18% | +6.10% |
| 2025-02-10 | Q4 2024 | 3.12 | 3.67 | +17.63% | $536.6M | ✅ Beat | -7.52% | -3.88% | -8.35% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q3 FY26 · $716.0M total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| Oncology | 32.1% | $229.9M | +19.4% | $170.5M | $188.6M | $192.6M | $195.9M |
| Metabolic | 29.2% | $209.2M | +5.0% | $148.0M | $147.9M | $199.3M | $249.8M |
| Other | 14.0% | $100.0M | -6.1% | $95.8M | $118.1M | $106.4M | $88.3M |
| Central Nervous System | 11.7% | $83.6M | +27.5% | $54.9M | $61.1M | $65.6M | $73.2M |
| Cardiology | 8.6% | $61.4M | +3.3% | $58.3M | $58.6M | $59.5M | $63.0M |
| Antiviral And Anti Infective | 4.4% | $31.8M | -12.9% | $31.1M | $29.1M | $36.5M | $38.3M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.